TRIB TRINITY BIOTECH PLC IFRS
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 888721 · Fiscal year ends 12/31
Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY12.8%
TTM net income YoY77.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.9%
Net income 3-yr CAGR—
Margins
Gross margin47.6%
Operating margin0.1%
Net margin-6.3%
FCF margin20.2%
EBITDA margin0.1%
Returns
ROE-512.3%
ROA-4.9%
ROIC (approx.)0.1%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets101.7%
Debt / equity—
Current ratio3.08x
Interest coverage0.01x
Cash quality & payout
Operating cash flow / net income-3.72x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $61.55M | $56.83M |
| Cost of revenue | $40.11M | $37.38M |
| Gross profit | $21.44M | $19.45M |
| R&D expense | $4.54M | $4.38M |
| SG&A expense | $28.82M | $31.15M |
| Operating income | -$21.16M | -$27.05M |
| Interest expense | $9.56M | $11.05M |
| Pretax income | -$30.73M | -$36.93M |
| Income tax | $486,000 | -$59,000 |
| Net income | -$31.79M | -$24.02M |
| EBITDA | -$20.96M | -$27.05M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $5.17M | $3.69M |
| Receivables | $16.07M | $13.90M |
| Inventory | $19.37M | $19.93M |
| Current assets | $41.12M | $39.04M |
| PP&E, netmay include right-of-use assets (IFRS) | $4.62M | $1.89M |
| Total assets | $103.29M | $59.44M |
| Current liabilities | $32.09M | $15.04M |
| Short-term debt | — | $210,000 |
| Long-term debt | $210,000 | $210,000 |
| Total debt | $210,000 | $420,000 |
| Total liabilities | $138.47M | $83.38M |
| Shareholders' equity | -$35.18M | -$23.95M |
| Net debt | -$4.96M | -$3.27M |
| Cash flow statement | ||
| Operating cash flow | -$4.19M | -$11.56M |
| Capital expenditure | $405,000 | $803,000 |
| Free cash flow | -$4.60M | -$12.36M |
| Investing cash flow | -$22.97M | $24.76M |
| Financing cash flow | $28.81M | -$16.04M |
| Depreciation & amortization | $204,000 | $0 |
| Stock-based compensation | $1.32M | $2.07M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.